Fructose and sugar: A major mediator of non-alcoholic fatty liver disease.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing mechanistic, experimental, and early clinical literature without systematic review methodology
PubMed 29408694 · doi:10.1016/j.jhep.2018.01.019
What was done
This narrative review synthesized experimental and clinical evidence evaluating the role of dietary sugar—specifically sucrose and high-fructose corn syrup (HFCS)—in the development and progression of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
What was found
The abstract reports no quantitative data or effect sizes. It describes mechanistic pathways whereby fructose metabolism via fructokinase C induces ATP consumption, nucleotide turnover, and uric acid production, leading to stimulated de novo lipogenesis and inhibited fat oxidation. It also notes roles for microbiome disruption, increased gut permeability, and endotoxemia, while citing early clinical evidence that restricting sugary drinks and added fructose reduces liver fat accumulation.
Why it matters
It outlines specific biochemical and gut-derived pathways connecting high fructose intake directly to steatohepatitis, pointing toward dietary reduction and uric acid inhibition as key targets for future definitive clinical trials.
Limits
The abstract provides no quantitative metrics, meta-analytic pooling, search criteria, or study counts. Findings rely heavily on mechanistic reasoning and early clinical trials requiring larger randomized confirmation.
Cited by
- supports Uric acid is a downstream metabolite of fructose.